Niagen Bioscience Inc (NAGE) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Niagen Bioscience Inc (NAGE) Healthcare & Pipeline Overview

Niagen Bioscience Inc specializes in biotechnology with a focus on healthy aging, leveraging groundbreaking research on nicotinamide adenine dinucleotide to position itself as a leader in the health and wellness market.

What Is the Investment Thesis for NAGE?

Niagen Bioscience Inc presents a compelling case for growth driven by its focus on the burgeoning healthy aging market, projected to reach $50 billion by 2028. The company's current P/E ratio of 15.63 and a profit margin of 14.3% indicate a solid financial foundation. Key value drivers include its proprietary research on NAD+, which is gaining traction among health-conscious consumers and investors alike. The ongoing global trend toward preventive healthcare further supports Niagen's growth potential. However, potential risks include market competition and regulatory challenges in the biotechnology sector. As the company continues to innovate and expand its product lines, it is well-positioned to capture a significant share of the growing demand for health and wellness solutions.

Based on FMP financials and quantitative analysis

NAGE Key Highlights

Market cap of $242M reflects solid investor interest in the biotechnology sector.

• Profit margin of 14.3% indicates operational efficiency and effective cost management.
• Gross margin of 64.3% exceeds industry averages, highlighting strong pricing power and product demand.
• Beta of 2.23 suggests higher volatility compared to the market, which may attract risk-tolerant investors.
• No dividend yield as the company reinvests profits into research and development.

Who Are NAGE's Competitors?

NAGE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are NAGE's Key Strengths?

Innovative research focus on NAD+ and healthy aging.

• Strong profit margins indicating operational efficiency.
• Proprietary formulations that differentiate products in the market.
• Established presence in the growing biotechnology sector.

What Are NAGE's Weaknesses?

Limited product offerings compared to larger competitors.

• No dividend yield may deter income-focused investors.
• Higher beta indicates potential volatility in stock performance.
• Dependence on a niche market may limit growth potential.

What Could Drive NAGE Stock Higher?

Launch of new NAD+ formulations aimed at specific health conditions expected in Q3 2026.

• Research collaborations with leading universities to enhance product efficacy and scientific validation.
• Participation in major biotechnology conferences to showcase research findings and product innovations in 2026.
• Expansion of e-commerce sales channels to increase market reach and consumer engagement.
• Potential partnerships with healthcare providers to integrate products into wellness programs.

What Are the Key Risks for NAGE?

Increased competition from larger biotechnology firms entering the healthy aging market.

• Regulatory scrutiny of health supplements could impact product approvals and market entry.
• Changes in consumer preferences may affect demand for NAD+ products.
• Economic downturns could reduce consumer spending on health and wellness products.

What Are the Growth Opportunities for NAGE?

• Growth opportunity 1: The global healthy aging market is projected to reach $50 billion by 2028, driven by increasing consumer demand for products that promote longevity. Niagen's focus on NAD+ research positions it to capitalize on this trend as consumers seek scientifically-backed solutions for age-related health issues.
• Growth opportunity 2: Expansion into international markets presents a significant opportunity for Niagen. As awareness of healthy aging grows globally, particularly in regions with aging populations such as Europe and Asia, Niagen can leverage its research to introduce its products to new customer bases, potentially increasing revenues substantially.
• Growth opportunity 3: Collaborations with academic institutions and research organizations can enhance Niagen's research capabilities and accelerate product development. By partnering on clinical trials and studies, Niagen can validate its products and expand its intellectual property portfolio, which can lead to new revenue streams.
• Growth opportunity 4: The rise of e-commerce and digital health platforms offers Niagen a unique channel to reach consumers directly. By establishing a strong online presence and utilizing digital marketing strategies, Niagen can effectively promote its products and engage with a broader audience, potentially increasing sales and brand recognition.
• Growth opportunity 5: Investment in R&D to develop new formulations and delivery methods for NAD+ supplements can enhance product efficacy and consumer appeal. As the market evolves, innovative product offerings can differentiate Niagen from competitors and drive growth in sales.

What Threats Does NAGE Face?

• Intense competition from established biotechnology firms.
• Regulatory challenges in the healthcare and supplement industries.
• Market saturation in the health supplement sector.
• Potential patent expirations could impact product exclusivity.

What Are NAGE's Competitive Advantages?

• Strong intellectual property portfolio protecting proprietary formulations.
• Established reputation in the biotechnology sector for innovative research.
• Focus on scientific validation of products enhances credibility and consumer trust.
• Niche market positioning in the growing healthy aging segment.
• Commitment to R&D ensures continuous product improvement and differentiation.

What Does NAGE Do?

Founded with a vision to enhance healthy aging, Niagen Bioscience Inc has established itself as a pioneering biotechnology firm based in Los Angeles, California. The company is dedicated to advancing research on nicotinamide adenine dinucleotide (NAD+), a crucial coenzyme involved in numerous biological processes including energy metabolism and DNA repair. Since its inception, Niagen has focused on the therapeutic potential of NAD+ and its role in promoting longevity and overall health. The company has developed proprietary formulations that are designed to boost NAD+ levels in the body, which may help mitigate age-related decline in cellular function. Niagen's innovative approach has garnered attention in the healthcare sector, particularly as the global population ages and the demand for effective anti-aging solutions increases. Operating with a workforce of 104 employees, Niagen has positioned itself strategically within the biotechnology landscape, aiming to capitalize on the growing interest in healthy aging and wellness products. The company is committed to rigorous scientific research and has built a portfolio of intellectual property that underscores its competitive advantage in the market. As Niagen continues to expand its research initiatives and product offerings, it remains focused on its mission to improve human health and longevity through scientific innovation.

What Products and Services Does NAGE Offer?

• Conduct research on nicotinamide adenine dinucleotide (NAD+) and its role in healthy aging.
• Develop proprietary formulations aimed at boosting NAD+ levels in the body.
• Focus on scientific innovation to create products that support longevity and overall health.
• Engage in collaborations with research institutions to advance understanding of NAD+.
• Market products that cater to health-conscious consumers seeking anti-aging solutions.
• Leverage intellectual property to protect and enhance product offerings.

How Does NAGE Make Money?

• Generate revenue through the sale of NAD+ boosting supplements and formulations.
• Engage in partnerships and collaborations that may provide additional funding and research opportunities.
• Utilize proprietary research to develop new products that can be patented and marketed.
• Focus on direct-to-consumer sales channels to maximize profit margins.
• Invest in R&D to continually innovate and expand product lines.

What Industry Does NAGE Operate In?

The biotechnology industry is experiencing rapid growth, driven by advancements in genetic research and an increasing focus on personalized medicine. Niagen Bioscience Inc fits into this landscape as a key player in the healthy aging segment, which is gaining prominence due to demographic shifts and rising consumer awareness about wellness. The competitive landscape includes both established pharmaceutical companies and emerging biotech firms, making innovation and research critical for market positioning.

Who Are NAGE's Key Customers?

• Health-conscious consumers interested in anti-aging solutions.
• Individuals seeking to improve their overall wellness and vitality.
• Researchers and institutions focused on aging and longevity studies.
• Retailers and e-commerce platforms that sell health and wellness products.
• Healthcare professionals recommending supplements to patients.

Niagen Bioscience Inc (NAGE) Valuation Context

Valued at $242M, NAGE is classified as a micro-cap stock. Analyst price targets span from $10.00 to $11.00, with a consensus of $10.33. At the current price of $3.04, that implies approximately 240% upside potential. Relative to its peer group, NAGE's quantitative score of 66/100 is below the peer average of 78/100.

NAGE Revenue & Earnings Trend

In Q2 FY2026, NAGE generated $29.8M in top-line revenue, marking a sequential decrease of 5.4%. The company recorded net income of $963K, with diluted EPS of $0.01. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, NAGE averaged $0.05 in diluted EPS.

Company Profile

Niagen Bioscience Inc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Los Angeles, US. The company is led by CEO Robert N. Fried. NAGE has traded publicly since 2015.

Return on equity for Niagen Bioscience Inc stands at 20.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 15.0%, showing how much profit it generates from its asset base. NAGE trades at a trailing price-to-earnings ratio of 15.63, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 2.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.50 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 6.1%, the inverse of the P/E and a quick read on earnings relative to price.

Niagen Bioscience Inc's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 6.65 places it in the safe zone, indicating low near-term bankruptcy risk.

Niagen Bioscience Inc has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 154.3% above estimates on average.

Over the past six months, Niagen Bioscience Inc insiders filed 12 SEC Form 4 transactions — 1 sales and 11 purchases. On net that is roughly 230K shares acquired (about $787K) — insiders putting money in tends to read as conviction.

NAGE Financials

NAGE Latest News

NAGE Analyst Consensus

NAGE MoonshotScore

What Investors Ask About Niagen Bioscience Inc (NAGE) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources